{"classes":[{"categories":[{"measurements":[{"comment":"For Palbociclib + Bortezomib + Dexamethasone (Phase1:Schedule A), reported DLTs were \\>1/6 (exceeding the MTD criteria), hence no MTD could be determined for Schedule A.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"MTD=highest dose level for which no more than 1 out of 6 participants experienced dose-limiting toxicity (DLT). DLT=any of the following treatment-related events: Absolute neutrophil count (ANC) less than (\\<)1000/microliter (mcL) (Grade 3 neutropenia) associated with documented infection/fever \\>=38.5degrees Celsius (C); Grade \\>=3 nonhematologic treatment-related toxicity, except those that were not maximally treated or considered tolerable, Grade 3 corrected QT interval (QTc) prolongation (QTc \\>500 millisecond \\[msec\\]) in asymptomatic participants even after repeat testing to exclude confounding factors and correction of reversible causes; Delay in the administration of Cycle 2 for more than 1 week of the planned date due to platelet count \\<25,000/mcL and/or ANC \\<500/mcL, or due to prolonged nonhematologic toxicities of Grade \\>=3; Inability to deliver at least 80 percent (%) of the planned PD 0332991 or bortezomib doses during Cycle 1 due to toxicity.","groups":[{"description":"Included all participants who received palbociclib (PD 0332991) 75 mg or 100 mg capsule orally once daily for 21 days followed by 7 days off-treatment in a 28-day cycle along with bortezomib 1.0 mg/m\\^2 intravenous injection and dexamethasone 20 mg tablet orally 30 minutes prior to bortezomib injection on Day 8, 11, 15 and 18 of 28-day cycle (schedule A) during Phase 1 of the study. Treatment was continued until any of the following withdrawal criteria was met: disease progression (unless the investigator judged that participant could still derive clinical benefit from continuing the treatment and the risk/benefit was still favorable), unacceptable toxicities, need for surgery or radiation therapy considered due to progressive disease by investigator, investigator conclusion that it is in the participant's best interest to discontinue therapy, need for anti-cancer therapy, lost to follow-up, withdrawal from treatment, or withdrawal of consent.","id":"OG000","title":"Palbociclib + Bortezomib + Dexamethasone (Phase1:Schedule A)"},{"description":"Included all participants who received palbociclib (PD 0332991) 100 mg or 125 mg capsule orally once daily for 12 days followed by 9 days off-treatment in a 21-day cycle along with bortezomib 1.0 mg/m\\^2 intravenous injection and dexamethasone 20 mg tablet orally 30 minutes prior to bortezomib injection on Day 8, 11, 15 and 18 of 21-day cycle (schedule B) during Phase 1 of the study. Treatment was continued until any of the following withdrawal criteria was met: disease progression (unless the investigator judged that participant could still derive clinical benefit from continuing the treatment and the risk/benefit was still favorable), unacceptable toxicities, need for surgery or radiation therapy considered due to progressive disease by investigator, investigator conclusion that it is in the participant's best interest to discontinue therapy, need for anti-cancer therapy, lost to follow-up, withdrawal from treatment, or withdrawal of consent.","id":"OG001","title":"Palbociclib + Bortezomib + Dexamethasone (Phase1:ScheduleB)"}],"paramType":"NUMBER","populationDescription":"DLT analysis set included all enrolled participants who received at least one dose of study treatment and did not have a major deviation in the first cycle.","reportingStatus":"POSTED","timeFrame":"Day 1 up to Day 28 during Cycle 1 in schedule A, Day 1 up to Day 21 during Cycle 1 in schedule B","title":"Maximum Tolerated Dose (MTD) of PD-0332991: Phase 1","type":"PRIMARY","unitOfMeasure":"milligram (mg)"}